Taiho Oncology

44 articles with Taiho Oncology

• Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual Meeting

  6/3/2022

  Taiho Oncology, Inc. announced today updated results of the Phase 2 FOENIX-CCA2 trial of futibatinib, confirming results observed in an earlier analysis. The trial was conducted in patients with locally advanced or metastatic unresectable intrahepatic (inside the liver) cholangiocarcinoma (iCCA) harboring FGFR2 gene rearrangements including fusions.

• U.S. Food and Drug Administration (FDA) Accepts for Priority Review Taiho Oncology's New Drug Application for Futibatinib for Cholangiocarcinoma

  3/30/2022

  Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for futibatinib.

• Taiho Oncology Recognizes the Important Role of Advocacy Organizations in Marking National Colorectal Cancer Awareness Month

  3/1/2022

  As part of Colorectal Cancer Awareness Month throughout March, Taiho Oncology, Inc., a company focused on advancing care in colorectal and other cancers, is calling for greater awareness of both the unique challenges faced by patients living with this disease, and of the resources and support required to help patients navigate their journey.

• Taiho Oncology To Share Data in Advanced Solid Tumors at ESMO Congress 2021

  9/13/2021

  Taiho Oncology, Inc. which specializes in orally administered anti-cancer medicines and whose mission is to improve the lives of patients with cancer, their families and their caregivers, announced data presentations from several studies for two of its investigational agents at the European Society for Medical Oncology Congress 2021.

• Taiho Oncology Announces Presentation of Phase 2 Data for Futibatinib (TAS-120) in Advanced Intrahepatic Cholangiocarcinoma at Virtual AACR Annual Meeting 2021

  4/11/2021

  Taiho Oncology, Inc. announced efficacy and safety results from the Phase 2 FOENIX-CCA2 trial, a single-arm multicenter Phase 2 study evaluating futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements including gene fusions who have failed at least one line of therapy.

• Taiho Oncology To Present Phase 2 Data for Futibatinib (TAS-120) in Advanced Intrahepatic Cholangiocarcinoma at Virtual AACR Annual Meeting 2021

  4/2/2021

  Taiho Oncology, Inc. today announced that Phase 2 clinical data, along with preclinical and Phase 1 clinical data for futibatinib (TAS-120) will be presented during the American Association for Cancer Research (AACR) Annual Meeting 2021 Week 1, taking place virtually from April 10-15, 2021 .

• FDA Grants Breakthrough Therapy Designation for Taiho Oncology's Futibatinib for Treatment of Advanced Cholangiocarcinoma

  4/1/2021

   Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for futibatinib (TAS-120)

• Taiho Oncology and Servier To Present Data on LONSURF® (trifluridine and tipiracil) at 2021 ASCO Gastrointestinal Cancers Symposium (ASCO GI)

  1/12/2021

  Taiho Oncology, Inc. and Servier today announced that data for LONSURF ® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer (mGC) and metastatic gastroesophageal junction adenocarcinoma (mGEJC) will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers

• Taiho Oncology, Inc. Announces Establishment of European Headquarters

  12/9/2020

  - European presence represents an important milestone in Taiho Oncology's expanding global pharmaceutical operations

• Taiho Oncology and Astex Pharmaceuticals To Present Data In Myelodysplastic Syndromes at the 62nd ASH Annual Meeting and Exposition

  12/2/2020

  Taiho Oncology, Inc. and Astex Pharmaceuticals, Inc. today announced that data for oral decitabine and cedazuridine (INQOVI® [decitabine and cedazuridine] 35mg/100mg tablets) in intermediate and high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) will be presented during the 62nd Annual American Society of Hematology Meeting and Exposition (ASH 2020),

• Taiho Oncology Launches World of Hope Campaign to Support MDS World Awareness Day

  10/23/2020

   Taiho Oncology, Inc., today announced the launch of its World of Hope campaign to support patients living with myelodysplastic syndrome (MDS) and bring much-needed attention to this rare and difficult-to-treat cancer during MDS World Awareness Day on October 25, 2020 . MDS is a rare blood cancer that impacts approximately 4 to 5

• Taiho Oncology To Present Futibatinib (TAS-120) Data In Advanced Intrahepatic Cholangiocarcinoma at ESMO Virtual Congress 2020

  9/15/2020

  Taiho Oncology, Inc. today announced data from three abstracts for futibatinib (TAS-120) in intrahepatic cholangiocarcinoma (iCCA) and in advanced solid tumors will be presented during the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21, 2020 . Key presentations include:

• Stephen Yoder, MD, MBA Named Vice President, Business Development, at Taiho Oncology, Inc.

  7/15/2020

  As Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd., continues to add early- and late-stage assets to its expanding oncology portfolio, the company announced the hiring of Stephen Yoder, MD, MBA as Vice President, Business Development, effective June 15, 2020.

• Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020

  6/4/2020

   Taiho Oncology, Inc. today announced that preclinical data for futibatinib (TAS-120) will be presented online during the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 from June 22-24 . Key presentations include:

• Taiho Oncology Announces Presentation of Data for Futibatinib in Advanced Intrahepatic Cholangiocarcinoma at 2020 ASCO Meeting

  5/31/2020

  Taiho Oncology, Inc. announced efficacy and safety results of an interim analysis of FOENIX-CCA2, a single-arm multicenter Phase 2 study evaluating futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements, who have failed at least one line of therapy.

• Taiho Oncology Supports Advocacy Efforts During National Colorectal Cancer Awareness Month

  3/2/2020

  Taiho Oncology, Inc., announced today the support and sponsorship of vital awareness, research and patient access initiatives from leading colorectal cancer advocacy organizations, including Colorectal Cancer Alliance, Fight Colorectal Cancer and PALTOWN's COLONTOWN ® , during National Colorectal Cancer Awareness Month in March.

• Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)

  1/25/2020

  Data include pooled safety analysis of Phase III trials of LONSURF in patients with metastatic colorectal cancer and metastatic gastric/gastroesophageal junction cancer, updates on futibatinib trials in progress

• Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology

  10/14/2019

  Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine

• Taiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals' Drug Candidates

  6/7/2019

  Taiho Oncology, Inc. announces that it has assumed commercialization responsibility from Otsuka Pharmaceuticals Co., Ltd., (Otsuka) for the novel fixed-dose combination of cedazuridine and decitabine (ASTX727) and guadecitabine (SGI-110) in the U.S. and Canada, subject to regulatory approvals.

• Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Data at the 2019 ASCO Annual Meeting

  6/3/2019

  Taiho Oncology, Inc. and Servier announced today clinical data with LONSURF® (trifluridine and tipiracil, TAS-102) in previously treated patients with metastatic gastric cancer (mGC), metastatic gastroesophageal junction adenocarcinoma (mGEJC) and metastatic colorectal cancer (mCRC) were presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.